Retrospective Analysis to Describe Patient Profiles, Current Treatment Patterns and Economic Burden for Asthma Patients in UAE. A Descriptive Analysis of the Asthma Patient Population in the Emirate of Dubai With Respect to Healthcare Resource Utilization, Costs, and Asthma-related Treatment Pattern

Asthma Clinical Trial

Official title:

Retrospective Analysis to Describe Patient Profiles, Current Treatment Patterns and Economic Burden for Asthma Patients in UAE.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03963141
• Other study ID #: D2287R00139
• Status: Completed
• Start date: August 31, 2019
• Est. completion date: October 31, 2022

Study information

• Verified date: May 2024
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This Retrospective cohort study with an overall objective of to perform a descriptive analysis of the asthma patient population in the Emirate of Dubai with respect to healthcare resource utilization, costs, and asthma-related treatment patterns and outcome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40541
• Est. completion date: October 31, 2022
• Est. primary completion date: October 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Minimum two claims with asthma diagnosis, 30 days apart, during the identification period

• Minimum 12 months of baseline period

• Age = 18 years on the index date

• Continuous enrolment during the baseline period and at least 180 days of follow-up period; enrolment will be defined based on at least one activity during each 90-day period from the index date

Exclusion Criteria:

• Diagnosis of COPD during the baseline period. Diagnosis of COPD will be defined as =1 medical claim with an ICD-10 diagnosis in any position

Related Conditions & MeSH terms

• Asthma
• Financial Stress

Locations

Country	Name	City	State
United Arab Emirates	Dha Claim	Dubai

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

United Arab Emirates, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Asthma Patients Number	Number of unique asthma patients in the database during December 2015 through November 2018(summarized annually).it will be computed in the follow-up period and will be reported as a percentage and number of visits per person per year (PPPY). Utilization will be considered "all-cause" if the associated medical claim(s) has a diagnosis code in any position for any condition.	1 Year
Primary	Asthma-related Cost	Total asthma-related cost reported in the databse during December 2015 through November 2018(summarized annually).It will will be computed in the follow-up period and will be reported as a percentage and number of visits per person per year (PPPY). Utilization will be considered "asthma-related" if the associated medical claim(s) has ICD-10 diagnosis code for asthma as the principal diagnosis	1 Year
Secondary	Asthma-related hopitalizations cost	Number of asthma related hopistalizations and cost reported in the database during December 2015 through Novemebr 2018(Summairzed annually)	1 Year
Secondary	Astma-related prescription pattern	Prescription pattern of asthma-related medication by drug class during December 2015 through November 2018	1 Year
Secondary	Severity of Asthma per total number of patients	Number of patients classified as Mild, moderate and severe asthmatic patinets as per the international guidlines.	1 Year

External Links

•   CSR Synopsis